References in periodicals archive ?
AVL-192 is a novel, orally available compound that can rapidly and completely silence the HCV protease through highly selective, irreversible covalent bonding to the target protein.
The covalent bonding mechanism of Avila Therapeutics' drugs has unique properties to effectively 'silence' disease-causing proteins.
AVL-181 and AVL-192 are novel, orally-available compounds that can rapidly and completely silence the HCV protease (also known as NS3) through highly selective, irreversible covalent bonding to the target protein.
How the analyte's transition into the gas phase changes covalent bonding
The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface uses end-point covalent bonding to keep the heparin anchored to the endoprosthesis surface over time.
The covalent bonding mechanism of Avila Therapeutics' drugs have unique properties to effectively 'silence' disease-causing proteins because they establish a strong and enduring 'bond' - exceeding the more temporary 'binding' of conventional drugs - to completely shut down the activity of, and silence, a disease-causing protein.
The GORE VIABAHN([R]) Endoprosthesis with PROPATEN Bioactive Surface will be used in the Gore REVISE Study, featuring the proprietary end-point covalent bonding of heparin, similar to the recently launched GORE PROPATEN Vascular Graft used in dialysis access.
It is designed to address the gap in clinical performance between synthetic and vein grafts by bonding the anticoagulant drug heparin to the surface of the graft using a proprietary end-point covalent bonding mechanism.
The GORE VIABAHN([R]) Endoprosthesis with Heparin Bioactive Surface uses end-point covalent bonding to keep the heparin anchored to the endoprosthesis surface over time.
The GORE VIABAHN[R] Endoprosthesis devices used in the Gore REVISE study will feature the proprietary end-point covalent bonding of heparin, similar to the recently launched GORE PROPATEN Vascular Graft used in AV access.
The GORE VIABAHN[R] Endoprosthesis devices used in the AVIATOR study will feature the proprietary end-point covalent bonding of heparin, similar to the recently launched GORE PROPATEN Vascular Graft used in AV access.